Arvinas price target raised to $14 from $10 at BTIG

BTIG raised the firm’s price target on Arvinas (ARVN) to $14 from $10 and keeps a Buy rating on the shares. Shares have sold off following the vepdeg reset, but the combination of current valuation, potential of KRASG12D as a target in large indications such as NSCLC and PDAC, and ability for ARV-806 to clinically differentiate all have the firm leaning into the stock ahead of the data, the analyst tells investors in a research note, adding that the firm is also including ARV-806 in its model.